Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that it has entered into a development support agreement with Intermountain Health, creating the framework for the two organizations to partner on a number of future studies evaluating the potential clinical, social, and economic value of using Perimeter’s optical coherence tomography (OCT) and collecting additional data to support the continued development of the company’s AI algorithms.
In the first of these studies, Intermountain Health will support a retrospective analysis of population level reoperation rates and incremental healthcare costs associated with reoperation for patients who underwent initial breast-conserving surgery (BCS) at select hospital sites.
“At Intermountain Health, we understand the significance of innovation, like Perimeter’s proprietary wide-field OCT interoperative margin assessment technology, that has the potential to optimize surgical oncology outcomes for patients, and support efficient delivery of care,” said Teresa Reading, MD, medical director, breast surgery, Canyons Region at Intermountain Health, who is involved with the clinical use of this technology. “We look forward to initiating this first study among our BCS patient population, as well as potentially expanding to other tissue types in the future.”
In a statement, Adrian Mendes, CEO of Perimeter, commented, “Intermountain Health is a fully integrated healthcare delivery system. It shares our commitment to improving both the patient and provider experience through innovation. And, with its own health plan, Intermountain Health is uniquely positioned to evaluate the total cost of cancer reoperations—not only to the patient, but also to the payer. We are excited about how this partnership can help shape our commercial and market access strategies as we work to advance not only our next-generation, AI-enabled Perimeter OCT system for use during BCS through the FDA PMA approval process, but also as we look to expand into other tissue types beyond breast.”
Perimeter is working to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.
The company is currently commercializing its FDA-cleared Perimeter S-Series OCT system, which provides real-time, cross-sectional visualization of excised tissues at the cellular level.
The company’s breakthrough-device-designated investigational Perimeter B-Series OCT system, which combines its proprietary ImgAssist artificial intelligence technology with wide field OCT, represents its next-generation device. In March 2025, the company submitted a PMA application to the FDA for the Perimeter B-Series for use during BCS in the U.S. The FDA PMA submission represented the achievement of a major milestone – Perimeter’s first pre-market regulatory submission for its AI-enabled wide-field OCT technology, as well as for a specific indication label. The PMA is currently under review with the FDA.
